---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-090153"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:41:23.162205+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15

## Summary
- Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.
- Post-sale shares outstanding 1,496,771; cash balance approximately $7.4M as of Oct 23, 2024.
- Proceeds to fund tecarfarin development and preparation for pivotal Phase 3 trial.
- H.C. Wainwright acted as exclusive sales agent; shelf registration effective March 20, 2024.

## SEC filing metadata
- accession: 0001213900-24-090153
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/0001213900-24-090153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/ea0218502-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-090153
- JSON: https://secwatch.observer/filing/0001213900-24-090153.json
- Plain text: https://secwatch.observer/filing/0001213900-24-090153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.